ETA2024 Poster Presentations Hyperthyroidism (9 abstracts)
Quality of life in graves disease: does type of treatment matter?
Nicolas Perini 1 , Juliana Carlini 2 , Roberto Santos 3 , Joao Romaldini 4 & Danilo Villagelin 3
1Hospital Puc-Campinas, Endocrinology, Campinas, Brazil; 2Pós-Graduação Em Clínica Médica Unicamp, Endocrinologia, Campinas, Brazil; 3Pontificia Universidade Católica de Campinas, Hospital Puc-Campinas, Endocrinology, Brazil; 4Pontificia Universidade Católica de Campinas, Endocrinology, Brazil
Introduction: Graves’ disease (GD) is the foremost cause of hyperthyroidism, and antithyroid drugs (ATD) are the first line of treatment, with around 40% of relapse after withdrawal. Therefore, radioiodine treatment (RAI) or a second course of ATD is indicated. However, the impact of those treatments on quality of life (QoL) is not well known.
Objectives: Investigate the impact of ATD and RAI in the QoL of relapsed GD patients.
Materials and Methods: Eighty-eight patients with GD relapse were evaluated in the euthyroid state (normal TSH and free T levels), according to the Thy-PRO 39 questionnaire. Group 1(n = 44, 54 ± 12 years; 85% was female) comprised patients on the second course of ATD, and Group 2 (n = 26, 56 ± 11 years; 96% was female) consisted of RAI-treated patients (and levothyroxine replacement) while remission patients represented Group 3 (n = 18, 56 ± 13 years; 100% was female).
Results: There was no statistically significant difference (P> 0.05 by ANOVA) between the three groups concerning age, sex, and the mean clinical activity score. The total of the Thy-Pro 39 questionnaire regarding patient symptoms about goiter, hypothyroidism, hyperthyroidism, eye symptoms, tiredness, cognitive complaints, anxiety, depression, emotional susceptibility, social impact, impact on daily life, and impact on appearance did not show any difference between the three groups either.
| Group 1(n = 44) | Group 2 (n = 26) | Group 3 (n = 18) | P-value | |
| FT3 (ng/dL) | 3.54 ± 0.98 | 3.02 ± 0.38 | 2.83 ±0.71 | 0.006 |
| T3T (ng/dL) | 1.34 ± 0.61 | 0.91 ± 0.13 | 1.37 ± 0.78 | 0.001 |
| TT4/TT3 | 0.12 ±0.04 | 0.09 ± 0.02 | 0.14 ± 0.07 | 0.009 |
| TSH (uUI/ml) | 1.96 ± 1.34 | 2.54 ± 1.89 | 2.51 ± 1.27 | NS |
| FT4 (ng/dL) | 1.26 ± 0.38 | 1.39 ± 0.36 | 1.25 ± 0.09 | NS |
| TT4 (ug/dL) | 10.2 ± 3.0 | 10.3 ± 1.8 | 9.7 ± 0.9 | NS |
| CAS | 0.4 ± 0.8 | 0.4 ± 0.6 | 0.4 ± 0.5 | NS |
| Group 2 patients had a lower T3T and TT3/TT4 ratio than groups 1 and 3 but no correlation with symptoms in the ThyPro 39 questionnaire. | ||||
Conclusion: Our results indicate that QoL in GD patients on ATD or RAI (with levothyroxine replacement) treatment is similar to remission patients, with patients treated with levothyroxine replacement presenting lower T3T and TT3/TT4 ratio.
Article tools
My recent searches
My recently viewed abstracts
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more